Frankfurt | Reuters – Bayer shares fell to their lowest levels in more than seven months after the German agricultural and pharmaceuticals group reported lower-than-expected second-quarter core earnings due to higher production costs and currency headwinds.
Second-quarter earnings before interest, tax, depreciation and amortisation (EBITDA) before special items fell 10.6 percent to 2.58 billion euros ($3.05 billion), missing the 2.79 billion forecast analysts had expected on average.
Shares in the group fell by as much as 6.1 percent to the bottom of the DAX, hitting their lowest since Dec. 21, 2020, after second-quarter adjusted EBITDA at Bayer’s Crop Science division declined by more than a quarter.
Read Also
Alberta crop conditions improve: report
Varied precipitation and warm temperatures were generally beneficial for crop development across Alberta during the week ended July 8, according to the latest provincial crop report released July 11.
“Higher prices and volumes, along with contributions from ongoing efficiency programmes only partly offset an increase in costs,” Bayer said in a statement.
Barclays analysts said investors might be concerned by the impact of cost inflation at the Crop Science division, which includes the Roundup weedkiller brand Bayer acquired as part of the $63 billion takeover of Monsanto.
The decline in core earnings overshadowed Bayer’s lifted full-year outlook, following stronger sales of prescription medicines that recovered from restrictions related to the COVID-19 pandemic.
Bayer expects sales of 43 billion euros this year, up from 41 billion earlier. EBITDA before special items is seen at 10.6 billion to 10.9 billion euros, compared with 10.5 billion to 10.8 billion previously.
The more optimistic outlook was partly driven by Bayer’s pharmaceuticals division, where second-quarter sales rose 16.2 percent and which is being strengthened by the acquisition of Vividion Therapeutics for up to $2 billion.
“Vividion’s unique technologies and special expertise will significantly strengthen our drug discovery capabilities,” Bayer Chief Executive Werner Baumann said in a statement.
Bayer last week said it would book additional provisions of $4.5 billion related to litigation, which alleges that Roundup can cause cancer, bringing the total to $16.1 billion.
Bayer said it would file in August a petition with the U.S. Supreme Court seeking a review of a lower court ruling that went in favour of Roundup user Edwin Hardeman. ($1 = 0.8451 euros)
